Telmisartan Teva

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
25-03-2021
Tabia za bidhaa Tabia za bidhaa (SPC)
25-03-2021

Viambatanisho vya kazi:

Telmisartan

Inapatikana kutoka:

Teva B.V.

ATC kanuni:

C09CA07

INN (Jina la Kimataifa):

telmisartan

Kundi la matibabu:

Agents acting on the renin-angiotensin system

Eneo la matibabu:

Hypertension

Matibabu dalili:

Treatment of essential hypertension in adults

Bidhaa muhtasari:

Revision: 11

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2010-01-25

Taarifa za kipeperushi

                                43
B. PACKAGE LEAFLET
44
PACKAGE LEAFLET: INFORMATION FOR THE USER
TELMISARTAN TEVA 20 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Telmisartan Teva is and what it is used for
2.
What you need to know before you take Telmisartan Teva
3.
How to take Telmisartan Teva
4.
Possible side effects
5.
How to store Telmisartan Teva
6.
Contents of the pack and other information
1.
WHAT TELMISARTAN TEVA IS AND WHAT IT IS USED FOR
Telmisartan Teva belongs to a class of medicines known as
angiotensin-II receptor antagonists.
Angiotensin II is a substance occurring in the body, which causes your
blood vessels to narrow, thus
increasing your blood pressure. Telmisartan Teva blocks this effect of
angiotensin II so that the blood vessels
relax, and your blood pressure is lowered.
Telmisartan Teva is used to treat essential hypertension (high blood
pressure) in adults. ‘Essential’ means
that the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead sometimes
to heart attacks, heart or kidney failure, strokes or blindness. There
are usually no symptoms of high blood
pressure before damage occurs. Thus it is important to regularly
measure blood pressure to verify if it is
within the normal range.
Telmisartan Teva is also used to reduce cardiovascular events (i.e.
heart attack or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, 
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Telmisartan Teva 20 mg tablets
Telmisartan Teva 40 mg tablets
Telmisartan Teva 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Telmisartan Teva 20 mg tablets
Each tablet contains 20 mg telmisartan
Telmisartan Teva 40 mg tablets
Each tablet contains 40 mg telmisartan
Telmisartan Teva 80 mg tablets
Each tablet contains 80 mg telmisartan
Excipients with known effect:
Telmisartan Teva 20 mg tablets
Each tablet contains 21.4 mg sorbitol (E420)
Telmisartan Teva 40 mg tablets
Each tablet contains 42.8 mg sorbitol (E420)
Telmisartan Teva 80 mg tablets
Each tablet contains 85.6 mg sorbitol (E420)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Telmisartan Teva 20 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7458".
Telmisartan Teva 40 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7459".
Telmisartan Teva 80 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7460".
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
3
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:
•
manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or peripheral
arterial disease) or
•
type 2 diabetes mellitus with documented target organ damage
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Treatment of essential hypertension _
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of 20 mg.
In cases where the target blood pressure is not achieved, the dose of
telmisartan can be increased to a
maximum
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kibulgaria 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kihispania 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kicheki 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kidenmaki 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kijerumani 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiestonia 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kigiriki 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kifaransa 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiitaliano 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kilatvia 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kilithuania 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kihungari 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kimalta 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiholanzi 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kipolandi 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kireno 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiromania 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kislovakia 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kislovenia 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kifinlandi 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiswidi 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 26-06-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kinorwe 25-03-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 25-03-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 25-03-2021
Tabia za bidhaa Tabia za bidhaa Kroeshia 25-03-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 26-06-2015

Tafuta arifu zinazohusiana na bidhaa hii